Science & Innovation
Diversified Product Portfolio
Our R&D efforts are the cornerstone of our mission to become a frontrunner in the development of medicines that address a range of unmet needs. By investing in cutting-edge research, we have established ourselves as global leaders in both generics and complex generics while paving the way for advances in specialty pharmaceuticals.
Our Efforts
Our R&D efforts are the cornerstone of our mission to become a frontrunner in the development of medicines that address a range of unmet needs. By investing in cutting-edge research, we have established ourselves as global leaders in both generics and complex generics while paving the way for advances in specialty pharmaceuticals.
Our Teams
Our R&D teams across the US, India and Europe are dedicated to developing a broad range of generic and complex generics products across the entire spectrum of routes of administration and dosage forms, with special attention to inhalation delivery and respiratory products. Additionally, our teams at Nanomi lead the way in developing controlled-release microspheres and nanoparticles, harnessing the power of proprietary Microsieve technology for advanced parenteral drug delivery.
Nanomi-Microsieve Technology
Nanomi’s Microsieve technology is a proprietary, highly scalable process that enables us to manufacture highly uniform microspheres and nanoparticles, ideal for long-acting injectable medicines. This innovative platform enhances the precision, consistency, and injectability of controlled-release products. Our technology makes producing microspheres and nanoparticles more cost-effective, reproducible, and adaptable to various therapeutic needs.
Respiratory Research
Inhalation therapy has emerged as a critical route for drug delivery, particularly in respiratory care. By directly targeting the lungs, inhalation allows for high pulmonary drug concentrations while minimizing systemic exposure, reducing the risk of side effects. This makes it the optimal choice for treating chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), where rapid and localized drug action is essential.
At Lupin, we have been at the forefront of pioneering advancements in inhalation therapy. Our expertise in this field has led us to be one of the first companies to successfully genericize ProAir (Albuterol), a vital rescue medication for asthma and COPD patients, ensuring timely access to life-saving treatment. We also became the first to introduce a generic version of Spiriva Handihaler (Tiotropium), a dry powder inhaler used for long-term maintenance of COPD.
Our ongoing commitment to respiratory health drives us to continuously expand our portfolio of affordable and high-quality inhalation therapies. In addition to generics, we are actively working on the development of innovative, next-generation respiratory treatments to address unmet needs and improve patient outcomes.
CloseSearch Product
